Alzheimer’s Disease (AD) Treatment Principles Alzheimer’s Disease (AD)

Treatment goals in AD

Treatment goals There is currently no cure for AD.1 Consequently, alleviating the symptoms of AD, and delaying symptom progression, are meaningful therapeutic goals.2 Full reference details: Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532. 1. Winblad et al. Lancet Neurol 2016;15(5):455–532; 2. Geldmacher et al. J Nutr Health Aging 2006;10(5):417–429

Treatment goals There is currently no cure for AD.1 Consequently, alleviating the symptoms of AD, and delaying symptom progression, are meaningful therapeutic goals.2 Ideally, the patient should be maintained as close as possible to their cognitive, functional, and behavioral status at diagnosis, for as long as possible.2 In mild AD, treatment outcomes should focus on memory functions.1 In more severe AD, effects on activities of daily living (ADLs) and psychiatric and behavioral disturbances are more clinically relevant.1 Patients and families may find the real-life benefits of treatment to be the most meaningful, such as the ability to complete household tasks, to enjoy hobbies, and to participate in family activities.2 Full reference details: Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532. 1. Winblad et al. Lancet Neurol 2016;15(5):455–532; 2. Geldmacher et al. J Nutr Health Aging 2006;10(5):417–429

Global symptom severity Treatment goals There is currently no cure for AD.1 Consequently, alleviating the symptoms of AD, and delaying symptom progression, are meaningful therapeutic goals.2 AD is a progressive disease, and an untreated patient will decline over time.2 Treatment expectation versus expected decline in AD2 Time Severe Mild Global symptom severity Untreated Full reference details: Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532. 1. Winblad et al. Lancet Neurol 2016;15(5):455–532; 2. Geldmacher et al. J Nutr Health Aging 2006;10(5):417–429

Global symptom severity Treatment goals There is currently no cure for AD.1 Consequently, alleviating the symptoms of AD, and delaying symptom progression, are meaningful therapeutic goals.2 AD is a progressive disease, and an untreated patient will decline over time.2 A successful treatment will result in a shift of the curve to the right, representing both short-term improvement, and long-term slowed progression of symptoms.2 This would increase the amount of time that a patient spends in milder stages, relative to receiving no treatment.2 Treatment expectation versus expected decline in AD2 Time Severe Mild Global symptom severity Untreated Successful treatment Full reference details: Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532. 1. Winblad et al. Lancet Neurol 2016;15(5):455–532; 2. Geldmacher et al. J Nutr Health Aging 2006;10(5):417–429

Global symptom severity Treatment goals There is currently no cure for AD.1 Consequently, alleviating the symptoms of AD, and delaying symptom progression, are meaningful therapeutic goals.2 AD is a progressive disease, and an untreated patient will decline over time.2 A successful treatment will result in a shift of the curve to the right, representing both short-term improvement, and long-term slowed progression of symptoms.2 This would increase the amount of time that a patient spends in milder stages, relative to receiving no treatment.2 The area between the ‘untreated’ and ‘successful treatment’ curves represents the benefit of the treatment.2 This benefit is maximized with early initiation of therapy.2 Treatment expectation versus expected decline in AD2 Time Severe Mild Global symptom severity Untreated Successful treatment Full reference details: Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532. 1. Winblad et al. Lancet Neurol 2016;15(5):455–532; 2. Geldmacher et al. J Nutr Health Aging 2006;10(5):417–429

Global symptom severity Treatment goals There is currently no cure for AD.1 Consequently, alleviating the symptoms of AD, and delaying symptom progression, are meaningful therapeutic goals.2 AD is a progressive disease, and an untreated patient will decline over time.2 A successful treatment will result in a shift of the curve to the right, representing both short-term improvement, and long-term slowed progression of symptoms.2 This would increase the amount of time that a patient spends in milder stages, relative to receiving no treatment.2 The area between the ‘untreated’ and ‘successful treatment’ curves represents the benefit of the treatment.2 This benefit is maximized with early initiation of therapy.2 At present, AD treatments have not been shown to prolong life.2 Consequently, the trajectories of treated and untreated patients will converge in the later stages of the disease, when treatment no longer provides measurable benefits.2 Treatment expectation versus expected decline in AD2 Time Severe Mild Global symptom severity Untreated Successful treatment Full reference details: Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532. 1. Winblad et al. Lancet Neurol 2016;15(5):455–532; 2. Geldmacher et al. J Nutr Health Aging 2006;10(5):417–429

Symptomatic and disease-modifying treatments Treatments for AD can be theoretically classified according to whether they affect:1 the symptoms of the disease (‘symptomatic treatments’) the underlying pathology of the disease (‘disease-modifying treatments’).  The current treatments for AD are symptomatic; disease-modifying treatments are not yet available.2 Full reference details: Kennedy GJ. From symptom palliation to disease modification: implications for dementia care. Primary Psychiatry 2013. http://primarypsychiatry.com/from-symptom-palliation-to-disease-modification- implications-for-dementia-care/. Accessed 26 August 2016. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006; 5 (11): 956–970. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532. 1. Kennedy. Primary Psychiatry. 2013; 2. Winblad et al. Lancet Neurol 2016;15(5):455–532; 3. Adapted from: Van Dam & De Deyn. Nat Rev Drug Discov 2006;5(11):956–970

Symptomatic and disease-modifying treatments Treatments for AD can be theoretically classified according to whether they affect:1 the symptoms of the disease (‘symptomatic treatments’) the underlying pathology of the disease (‘disease-modifying treatments’).  The current treatments for AD are symptomatic; disease-modifying treatments are not yet available.2 As shown on the previous screen, AD is a progressive disease, and an untreated patient will decline over time. Full reference details: Kennedy GJ. From symptom palliation to disease modification: implications for dementia care. Primary Psychiatry 2013. http://primarypsychiatry.com/from-symptom-palliation-to-disease-modification- implications-for-dementia-care/. Accessed 26 August 2016. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006; 5 (11): 956–970. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532. 1. Kennedy. Primary Psychiatry. 2013; 2. Winblad et al. Lancet Neurol 2016;15(5):455–532; 3. Adapted from: Van Dam & De Deyn. Nat Rev Drug Discov 2006;5(11):956–970

Symptomatic and disease-modifying treatments Treatments for AD can be theoretically classified according to whether they affect:1 the symptoms of the disease (‘symptomatic treatments’) the underlying pathology of the disease (‘disease-modifying treatments’).  The current treatments for AD are symptomatic; disease-modifying treatments are not yet available.2 A symptomatic treatment can provide an initial benefit, but the patient will continue to decline.1 The disease pathology will not be affected, and, if the treatment is withdrawn, the patient will return to the untreated trajectory.1 Full reference details: Kennedy GJ. From symptom palliation to disease modification: implications for dementia care. Primary Psychiatry 2013. http://primarypsychiatry.com/from-symptom-palliation-to-disease-modification- implications-for-dementia-care/. Accessed 26 August 2016. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006; 5 (11): 956–970. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532. 1. Kennedy. Primary Psychiatry. 2013; 2. Winblad et al. Lancet Neurol 2016;15(5):455–532; 3. Adapted from: Van Dam & De Deyn. Nat Rev Drug Discov 2006;5(11):956–970

Symptomatic and disease-modifying treatments Treatments for AD can be theoretically classified according to whether they affect:1 the symptoms of the disease (‘symptomatic treatments’) the underlying pathology of the disease (‘disease-modifying treatments’).  The current treatments for AD are symptomatic; disease-modifying treatments are not yet available.2 A disease-modifying treatment would either stop or slow the progressive decline of the patient.1 Consequently, the patient’s trajectory of decline would be less steep, diverging at an acute angle from that of an untreated patient.1 The larger the disease-modifying effect, the greater this divergence, and the sooner that the benefit of treatment would be clinically observable.1 Even when disease-modifying treatments become available, they will not necessarily restore a patient’s function to premorbid levels, and so symptomatic therapies will still have a role to play.1 Full reference details: Kennedy GJ. From symptom palliation to disease modification: implications for dementia care. Primary Psychiatry 2013. http://primarypsychiatry.com/from-symptom-palliation-to-disease-modification- implications-for-dementia-care/. Accessed 26 August 2016. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006; 5 (11): 956–970. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532. 1. Kennedy. Primary Psychiatry. 2013; 2. Winblad et al. Lancet Neurol 2016;15(5):455–532; 3. Adapted from: Van Dam & De Deyn. Nat Rev Drug Discov 2006;5(11):956–970

Symptomatic and disease-modifying treatments Treatments for AD can be theoretically classified according to whether they affect:1 the symptoms of the disease (‘symptomatic treatments’) the underlying pathology of the disease (‘disease-modifying treatments’).  The current treatments for AD are symptomatic; disease-modifying treatments are not yet available.2 A cure for AD would reverse the disease progress and restore the patient to their original level of functioning.3 Full reference details: Kennedy GJ. From symptom palliation to disease modification: implications for dementia care. Primary Psychiatry 2013. http://primarypsychiatry.com/from-symptom-palliation-to-disease-modification- implications-for-dementia-care/. Accessed 26 August 2016. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006; 5 (11): 956–970. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (5): 455–532. 1. Kennedy. Primary Psychiatry. 2013; 2. Winblad et al. Lancet Neurol 2016;15(5):455–532; 3. Adapted from: Van Dam & De Deyn. Nat Rev Drug Discov 2006;5(11):956–970

Key points Current treatments for AD are symptomatic; there is no cure, or disease-modifying treatment, that can affect the underlying pathology of the disease. Alleviating the symptoms of AD, and delaying symptom progression, are meaningful therapeutic goals. Even when disease-modifying treatments become available, they will not necessarily restore a patient’s function to premorbid levels – symptomatic therapies will still have a role to play.

Current approaches to AD management

Current approaches to AD management The management of AD can be categorized into pharmacological, psychosocial, and caregiving aspects. Dementia is a progressive disorder, and a patient’s treatment must evolve with time to address newly emerging issues.1 Furthermore, as the manifestation of dementia varies considerably from patient to patient, treatment plans should be individualized.1 Pharmacological Psychosocial Caregiving Full reference details: American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. APA. Guideline watch. 2014

Current approaches to AD management The management of AD can be categorized into pharmacological, psychosocial, and caregiving aspects. Dementia is a progressive disorder, and a patient’s treatment must evolve with time to address newly emerging issues.1 Furthermore, as the manifestation of dementia varies considerably from patient to patient, treatment plans should be individualized.1 Pharmacological therapies indicated for the treatment of AD are:1,2 acetylcholinesterase inhibitors (AChEIs) NMDA receptor antagonist. Other pharmacological therapies used in AD include:1,2 antipsychotics for psychosis and agitation antidepressants for depression sedatives for sleep disturbance. Pharmacological Psychosocial Caregiving Full reference details: American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. APA. Guideline watch. 2014

Current approaches to AD management The management of AD can be categorized into pharmacological, psychosocial, and caregiving aspects. Dementia is a progressive disorder, and a patient’s treatment must evolve with time to address newly emerging issues.1 Furthermore, as the manifestation of dementia varies considerably from patient to patient, treatment plans should be individualized.1 Psychosocial therapies include:1,2 behavior-oriented approaches stimulation-oriented approaches emotion-oriented approaches cognition-oriented approaches sleep hygiene. Pharmacological Psychosocial Caregiving Full reference details: American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. APA. Guideline watch. 2014

Current approaches to AD management The management of AD can be categorized into pharmacological, psychosocial, and caregiving aspects. Dementia is a progressive disorder, and a patient’s treatment must evolve with time to address newly emerging issues.1 Furthermore, as the manifestation of dementia varies considerably from patient to patient, treatment plans should be individualized.1 Family/caregiver support is a key part of the management of patients with AD. Pharmacological Psychosocial Caregiving Full reference details: American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. APA. Guideline watch. 2014

Current approaches to AD management The management of AD can be categorized into pharmacological, psychosocial, and caregiving aspects. Dementia is a progressive disorder, and a patient’s treatment must evolve with time to address newly emerging issues.1 Furthermore, as the manifestation of dementia varies considerably from patient to patient, treatment plans should be individualized.1 In addition to the emergence of new symptoms of AD with time, patients may require treatment for co-occurring psychiatric and medical conditions.1,2 Pharmacological Psychosocial Caregiving Full reference details: American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. APA. Guideline watch. 2014

Psychosocial therapies for AD The purpose of psychosocial therapy is to improve quality of life, and to maximize patient functioning in the context of existing deficits.1 Several different psychosocial therapies have been developed, which may be targeted towards the patient, or their family.1 In general, these psychosocial therapies have not been studied in randomized, double-blind, controlled trials, and do not provide lasting effects.1 Nonetheless, certain interventions are supported by research findings, and have gained clinical acceptance.1,2 Appropriate psychosocial therapies for a patient should be selected based on the availability and cost of the therapy, and the patient’s characteristics and preferences.1 Psychosocial therapies are generally administered daily or weekly.1 Behavior-oriented approaches Stimulation-oriented approaches Emotion-oriented approaches Full reference details: American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. Cognition-oriented approaches Sleep hygiene General psychosocial interventions 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. APA. Guideline watch. 2014

Psychosocial therapies for AD The purpose of psychosocial therapy is to improve quality of life, and to maximize patient functioning in the context of existing deficits.1 Several different psychosocial therapies have been developed, which may be targeted towards the patient, or their family.1 In general, these psychosocial therapies have not been studied in randomized, double-blind, controlled trials, and do not provide lasting effects.1 Nonetheless, certain interventions are supported by research findings, and have gained clinical acceptance.1,2 Appropriate psychosocial therapies for a patient should be selected based on the availability and cost of the therapy, and the patient’s characteristics and preferences.1 Psychosocial therapies are generally administered daily or weekly.1 The aim of behavior-oriented treatments is to identify problem behaviors and to reduce their frequency, by making changes to the patient’s environment.1 Examples of behavioral interventions are scheduled toileting (to reduce urinary incontinence), and aggressive-behavior management training for caregivers.1 Behavioral interventions are supported by small trials and case studies, and are in widespread clinical use.1,2 Behavior-oriented approaches Stimulation-oriented approaches Emotion-oriented approaches Full reference details: American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. Cognition-oriented approaches Sleep hygiene General psychosocial interventions 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. APA. Guideline watch. 2014

Psychosocial therapies for AD The purpose of psychosocial therapy is to improve quality of life, and to maximize patient functioning in the context of existing deficits.1 Several different psychosocial therapies have been developed, which may be targeted towards the patient, or their family.1 In general, these psychosocial therapies have not been studied in randomized, double-blind, controlled trials, and do not provide lasting effects.1 Nonetheless, certain interventions are supported by research findings, and have gained clinical acceptance.1,2 Appropriate psychosocial therapies for a patient should be selected based on the availability and cost of the therapy, and the patient’s characteristics and preferences.1 Psychosocial therapies are generally administered daily or weekly.1 The aim of stimulation-oriented treatments is to activate the patient’s available cognitive resources.1 Examples of stimulation interventions are recreational activities or therapies (e.g., crafts, games, pets), art therapies (e.g., music, dance, art), and exercise.1 Stimulation interventions have limited data to support their efficacy, but should be considered part of the humane care of patients with dementia.1,2 Behavior-oriented approaches Stimulation-oriented approaches Emotion-oriented approaches Full reference details: American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. Cognition-oriented approaches Sleep hygiene General psychosocial interventions 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. APA. Guideline watch. 2014

Psychosocial therapies for AD The purpose of psychosocial therapy is to improve quality of life, and to maximize patient functioning in the context of existing deficits.1 Several different psychosocial therapies have been developed, which may be targeted towards the patient, or their family.1 In general, these psychosocial therapies have not been studied in randomized, double-blind, controlled trials, and do not provide lasting effects.1 Nonetheless, certain interventions are supported by research findings, and have gained clinical acceptance.1,2 Appropriate psychosocial therapies for a patient should be selected based on the availability and cost of the therapy, and the patient’s characteristics and preferences.1 Psychosocial therapies are generally administered daily or weekly.1 The aims of emotion-oriented treatments are to address issues of loss, and to improve mood and behavior.1 Examples of emotion interventions are reminiscence therapy (in the context of the patient’s life history), validation therapy, and supportive psychotherapy.1 Emotion interventions have limited data to support their efficacy.1,2 Behavior-oriented approaches Stimulation-oriented approaches Emotion-oriented approaches Full reference details: American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. Cognition-oriented approaches Sleep hygiene General psychosocial interventions 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. APA. Guideline watch. 2014

Psychosocial therapies for AD The purpose of psychosocial therapy is to improve quality of life, and to maximize patient functioning in the context of existing deficits.1 Several different psychosocial therapies have been developed, which may be targeted towards the patient, or their family.1 In general, these psychosocial therapies have not been studied in randomized, double-blind, controlled trials, and do not provide lasting effects.1 Nonetheless, certain interventions are supported by research findings, and have gained clinical acceptance.1,2 Appropriate psychosocial therapies for a patient should be selected based on the availability and cost of the therapy, and the patient’s characteristics and preferences.1 Psychosocial therapies are generally administered daily or weekly.1 The aim of cognition-oriented treatments is to restore cognitive deficits, often in a classroom setting.1 Examples of cognition interventions are reality orientation, cognitive retraining, and skills training (focused on specific cognitive deficits).1 Cognition interventions may provide modest and transient improvements; however, they are associated with adverse emotional consequences (such as frustration).1,2 Behavior-oriented approaches Stimulation-oriented approaches Emotion-oriented approaches Full reference details: American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. Cognition-oriented approaches Sleep hygiene General psychosocial interventions 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. APA. Guideline watch. 2014

Psychosocial therapies for AD The purpose of psychosocial therapy is to improve quality of life, and to maximize patient functioning in the context of existing deficits.1 Several different psychosocial therapies have been developed, which may be targeted towards the patient, or their family.1 In general, these psychosocial therapies have not been studied in randomized, double-blind, controlled trials, and do not provide lasting effects.1 Nonetheless, certain interventions are supported by research findings, and have gained clinical acceptance.1,2 Appropriate psychosocial therapies for a patient should be selected based on the availability and cost of the therapy, and the patient’s characteristics and preferences.1 Psychosocial therapies are generally administered daily or weekly.1 Many patients with AD suffer from sleep disturbances, which may be minimized by their participation in daytime activities, and by improving sleep hygiene (e.g., consistent rising times, minimizing daytime napping, and daily exercise).1 Behavior-oriented approaches Stimulation-oriented approaches Emotion-oriented approaches Full reference details: American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. Cognition-oriented approaches Sleep hygiene General psychosocial interventions 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. APA. Guideline watch. 2014

Psychosocial therapies for AD The purpose of psychosocial therapy is to improve quality of life, and to maximize patient functioning in the context of existing deficits.1 Several different psychosocial therapies have been developed, which may be targeted towards the patient, or their family.1 In general, these psychosocial therapies have not been studied in randomized, double-blind, controlled trials, and do not provide lasting effects.1 Nonetheless, certain interventions are supported by research findings, and have gained clinical acceptance.1,2 Appropriate psychosocial therapies for a patient should be selected based on the availability and cost of the therapy, and the patient’s characteristics and preferences.1 Psychosocial therapies are generally administered daily or weekly.1 Patients should be periodically monitored for the evolution of cognitive symptoms and their response to intervention, and for matters of safety such as suicidality and aggressiveness.1 Patients should be advised against driving, due to the increased risk of traffic accidents.1 Patients and their families should be educated about AD, its treatment, and sources of additional care and support; also, families should be advised about the need for financial and legal planning due to the patient’s eventual incapacity.1 A therapeutic alliance should be established and maintained with the patient and their family.1 Behavior-oriented approaches Stimulation-oriented approaches Emotion-oriented approaches Full reference details: American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. Cognition-oriented approaches Sleep hygiene General psychosocial interventions 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. APA. Guideline watch. 2014

Disease-stage-specific treatment Due to the progressive nature of AD, a patient’s symptoms will evolve over time.1 Consequently, the treatment of dementia should be adapted to the stage of the disease.1 Medications aimed at improving cognition are prescribed based on disease stage,1 whereas nonpharmacological interventions and psychiatric medications are used independent of disease stage, based on the patient’s needs. With nonpharmacological interventions, it is critical to match the level of demand on the patient with his or her current capacities, so as not to frustrate or patronize the patient.2 Mildly impaired patients Moderately impaired patients Severely impaired patients Full reference details: APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429. Grossberg GT, Desai AK. Management of Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2003; 58 (4): 331–353. Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol 2015; 22 (6): 889–898. 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. Grossberg & Desai. J Gerontol A Biol Sci Med Sci 2003;58(4):331–353; 3. APA. Guideline watch. 2014; 4. Geldmacher et al. J Nutr Health Aging 2006;10(5):417–429; 5. Schmidt et al. Eur J Neurol 2015;22(6):889–898

Disease-stage-specific treatment Due to the progressive nature of AD, a patient’s symptoms will evolve over time.1 Consequently, the treatment of dementia should be adapted to the stage of the disease.1 Depression is common in patients with dementia.1 Regular counseling or psychological support can help patients to cope with the diagnosis.1,2 Depression may be treated with cognitive therapy, or with antidepressants.2,3 In mild AD, the use of diaries and recording devices can help patients to remember events and conversations.2 Medications aimed at improving cognition are prescribed based on disease stage,1 whereas nonpharmacological interventions and psychiatric medications are used independent of disease stage, based on the patient’s needs. With nonpharmacological interventions, it is critical to match the level of demand on the patient with his or her current capacities, so as not to frustrate or patronize the patient.2 Emotion-oriented approaches, such as supportive psychotherapy, reminiscence therapy, and validation therapy, are especially valuable in mild AD.2 Patients may also benefit from recreational activity.1 In terms of pharmacotherapy, patients with mild AD should be offered a trial of an AChEI.1 AChEIs modestly improve cognition in mild to moderate AD, and early treatment is associated with slower decline of cognitive function.3,4 Mildly impaired patients Moderately impaired patients Severely impaired patients Full reference details: APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429. Grossberg GT, Desai AK. Management of Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2003; 58 (4): 331–353. Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol 2015; 22 (6): 889–898. 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. Grossberg & Desai. J Gerontol A Biol Sci Med Sci 2003;58(4):331–353; 3. APA. Guideline watch. 2014; 4. Geldmacher et al. J Nutr Health Aging 2006;10(5):417–429; 5. Schmidt et al. Eur J Neurol 2015;22(6):889–898

Disease-stage-specific treatment Due to the progressive nature of AD, a patient’s symptoms will evolve over time.1 Consequently, the treatment of dementia should be adapted to the stage of the disease.1 In the moderate stages of dementia, patients may require supervision to remain safe.1 The patient’s caregiver may begin to feel more burdened, and respite care (e.g., home health aides, or day care) may be needed.1 Emotion-oriented approaches such as reminiscence therapy and validation therapy continue to be valuable in the moderate stages of AD.2 Behavior-oriented approaches are especially helpful for the treatment of depression in moderate AD.2 Medications aimed at improving cognition are prescribed based on disease stage,1 whereas nonpharmacological interventions and psychiatric medications are used independent of disease stage, based on the patient’s needs. With nonpharmacological interventions, it is critical to match the level of demand on the patient with his or her current capacities, so as not to frustrate or patronize the patient.2 In terms of pharmacotherapy, the addition of an NMDA receptor antagonist to an AChEI may be beneficial in delaying symptom progression among patients with moderate AD; however, the clinical significance of such augmentation is slight at best.1,3 Nonetheless, the desirable effects of combined AChEI and NMDA receptor antagonist treatment outweigh the undesirable effects in patients with moderate to severe AD.5 Pharmacological and/or nonpharmacological interventions are likely to be needed as patients begin to experience delusions and hallucinations, and as they suffer worsening agitation, aggression, and depression.1 Mildly impaired patients Moderately impaired patients Severely impaired patients Full reference details: APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429. Grossberg GT, Desai AK. Management of Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2003; 58 (4): 331–353. Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol 2015; 22 (6): 889–898. 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. Grossberg & Desai. J Gerontol A Biol Sci Med Sci 2003;58(4):331–353; 3. APA. Guideline watch. 2014; 4. Geldmacher et al. J Nutr Health Aging 2006;10(5):417–429; 5. Schmidt et al. Eur J Neurol 2015;22(6):889–898

Disease-stage-specific treatment Due to the progressive nature of AD, a patient’s symptoms will evolve over time.1 Consequently, the treatment of dementia should be adapted to the stage of the disease.1 In the severe stages of dementia, patients are incapacitated and almost completely dependent on others for help with basic ADLs, such as dressing, bathing, and feeding.1 As the patient worsens, he or she may need to be transferred to a nursing home.1,3 In terms of pharmacotherapy, NMDA receptor antagonist is approved for severe AD (as are certain AChEIs in some regions)1 Additional pharmacotherapy may be needed for psychotic symptoms and Medications aimed at improving cognition are prescribed based on disease stage,1 whereas nonpharmacological interventions and psychiatric medications are used independent of disease stage, based on the patient’s needs. With nonpharmacological interventions, it is critical to match the level of demand on the patient with his or her current capacities, so as not to frustrate or patronize the patient.2 agitation if they cause distress to the patient, or if they cause significant danger or disruption to caregivers or other nursing home residents.1 Depression can be difficult to diagnose at this stage of the disease.1 Feeding tube placement, treatment of infection, cardiopulmonary resuscitation, and intubation must be agreed in advance with the patient and their family.1 The treatment team should also help the family to prepare for the patient’s death.1 Mildly impaired patients Moderately impaired patients Severely impaired patients Full reference details: APA Work Group on Alzheimer’s Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, 2nd edition. Am J Psychiatry 2007; 164 (12 Suppl): 5–56. American Psychiatric Association; Rabins PV, Rovner BW, Rummans T, et al. Guideline watch for the practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. October 2014. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006; 10 (5): 417–429. Grossberg GT, Desai AK. Management of Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2003; 58 (4): 331–353. Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol 2015; 22 (6): 889–898. 1. APA. Am J Psychiatry 2007;164(12 Suppl):5–56; 2. Grossberg & Desai. J Gerontol A Biol Sci Med Sci 2003;58(4):331–353; 3. APA. Guideline watch. 2014; 4. Geldmacher et al. J Nutr Health Aging 2006;10(5):417–429; 5. Schmidt et al. Eur J Neurol 2015;22(6):889–898

Key points AD is managed through a combination of pharmacological, psychosocial, and caregiving approaches. Pharmacological therapies indicated for the treatment of AD are the AChEIs and NMDA receptor antagonist. Psychosocial therapies include those targeted at behavior, stimulation, emotions, cognition, and sleep hygiene. In general, evidence to support these therapies is limited. As the disease advances, patients with AD become increasingly dependent on caregivers. Consequently, the pressure on caregivers increases. Treatment plans should be individualized, and should evolve as the disease progresses.